Intestinal lymphoma: exploration of the prognostic factors and the optimal treatment.
Primary gastrointestinal (GI) lymphoma accounts for 4% to 20% of all non-Hodgkin's lymphomas (NHL), being the most common extranodal site of presentation. However, the optimal management of intestinal lymphoma has not yet been established. During the period of 1994 to 2001, we retrospectively analyzed the clinical features of 67 intestinal lymphoma patients diagnosed according to the Lewin's definitions. The most frequently involved location was ileocecal (35.8%) followed by small bowel (31.3%), large bowel (19.4%), and multiple GI involvement (13.4%). The estimated 5-year overall survival rate was 53%. Out of all treated patients, 49.2% achieved complete response. The advanced stage, poor performance and T-cell phenotype had an adverse prognostic influence on overall survival. In localized diseases (stage 1 and 2), the primary surgical treatment had the most favorable influence on failure-free survival (P < 0.05). The resection of localized intestinal lymphoma may be appropriate as the primary treatment.
Lee
Jeeyun
J
Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim
Won Seog
WS
Kim
Kihyun
K
Ko
Young Hyeh
YH
Kim
Jae Jun
JJ
Kim
Young Ho
YH
Chun
Ho Kyung
HK
Lee
Woo Yong
WY
Park
Joon Oh
JO
Jung
Chul Won
CW
Im
Young-Hyuck
YH
Lee
Mark H
MH
Kang
Won Ki
WK
Park
Keunchil
K
D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007414:Intestinal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome